QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 psychedelic-drugs-market-set-to-grow-by-137b-by-2028-driven-by-mental-health-disorders-and-ai-integration

The global psychedelic drugs market is projected to grow by USD 1.37 billion by 2028, driven by mental health needs and AI adva...

 hc-wainwright--co-reiterates-buy-on-atai-life-sciences-maintains-15-price-target

HC Wainwright & Co. analyst Patrick Trucchio reiterates ATAI Life Sciences (NASDAQ:ATAI) with a Buy and maintains $15 pr...

 atais-dmt-depression-drug-shows-promise-prepares-for-phase-ii-trial-and-future-collaboration-with-pharma-giant

Atai Life Sciences reports positive early data for its DMT-based depression treatment, VLS-01, and plans a Phase II trial targe...

 hc-wainwright--co-reiterates-buy-on-atai-life-sciences-maintains-15-price-target

HC Wainwright & Co. analyst Patrick Trucchio reiterates ATAI Life Sciences (NASDAQ:ATAI) with a Buy and maintains $15 pr...

 cantor-fitzgerald-reiterates-overweight-on-atai-life-sciences

Cantor Fitzgerald analyst Charles Duncan reiterates ATAI Life Sciences (NASDAQ:ATAI) with a Overweight.

 atai-life-sciences-announced-an-update-on-beckley-psytechs-phase-12a-trial-of-ele-101-for-major-depressive-disorder-with-initial-results-from-phase-1-and-the-dosing-of-the-first-patients-in-the-phase-2a-part-of-the-study

ELE-101 is a patent-protected, synthetic formulation of psilocin, designed to offer the therapeutic benefits of psilocybin in...

 psychedelic-stocks-trip-up-after-fda-advisors-reject-mdma-for-ptsd-treatment

FDA panel rejects MDMA therapy for PTSD, citing lack of evidence for benefits outweighing risks. Psychedelic stocks take a hit,...

 whats-going-on-with-mindmed-and-psychedelic-stocks

Mind Medicine (MindMed) shares are trading lower Wednesday after a Food and Drug Administration (FDA) panel rejected the approv...

 hc-wainwright--co-reiterates-buy-on-atai-life-sciences-maintains-15-price-target

HC Wainwright & Co. analyst Patrick Trucchio reiterates ATAI Life Sciences (NASDAQ:ATAI) with a Buy and maintains $15 pr...

 atai-life-sciences-q1-eps-017-beats-018-estimate-cash-1887m

ATAI Life Sciences (NASDAQ:ATAI) reported quarterly losses of $(0.17) per share which beat the analyst consensus estimate of $(...

 atai-life-sciences-announces-the-publication-of-beckley-psytechs-phase-1-study-of-bpl-003-in-the-journal-of-psychopharmacology

atai Life Sciences (NASDAQ:ATAI) ("atai" or "Company"), a clinical-stage biopharmaceutical company aiming to tr...

 cantor-fitzgerald-reiterates-overweight-on-atai-life-sciences

Cantor Fitzgerald analyst Charles Duncan reiterates ATAI Life Sciences (NASDAQ:ATAI) with a Overweight.

 why-ulta-beauty-shares-are-trading-lower-by-around-14-here-are-other-stocks-moving-in-wednesdays-mid-day-session

Shares of Ulta Beauty, Inc. (NASDAQ: ULTA) fell sharply during Wednesday’s session amid the company's presentation at the ...

 signet-jewelers-dave--busters-entertainment-blue-owl-capital-and-other-big-stocks-moving-higher-on-wednesday

U.S. stocks were higher, with the Dow Jones gaining over 50 points on Wednesday.

 maxim-group-upgrades-atai-life-sciences-to-buy-announces-6-price-target

Maxim Group analyst Jason McCarthy upgrades ATAI Life Sciences (NASDAQ:ATAI) from Hold to Buy and announces $6 price target.

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION